Efforts to combat the global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) range from adequate diagnostic testing and contract tracing to vaccination for the prevention of coronavirus disease 2019 (COVID-19). In the United States alone, three vaccinations have been authorized for emergency use (EUA) or approved to prevent COVID-19. The Ad26.COV2.S vaccine by Johnson and Johnson (New Brunswick, New Jersey) is the only adenovirus-based vaccine and deemed relatively effective and safe by the US Food and Drug Administration (FDA) following its clinical trial. Since its introduction, the US FDA has placed a warning on the vaccine adverse event reporting system (VAERS) after more than 100 cases of Guillain-Barre Syndrome (GBS) were reported. Herein, we outline the hospital course of a generally healthy 49-year-old female who experienced an axonal form of GBS nine days after receiving the Ad26.COV2.S vaccine.
【저자키워드】 COVID-19, COVID-19 vaccine, Autoimmune, Vaccine adverse events, Ad26.COV2.S vaccine, adenovirus vaccine, covid-19 vaccine complication, guillain-barre syndrome (gbs), vaccine adverse reactions, 【초록키워드】 coronavirus disease, SARS-CoV-2, Vaccine, vaccination, hospital, diagnostic, drug, FDA, EUA, global pandemic, adverse event, female, Emergency use, food, Safe, US FDA, Prevent, effective, Course, caused, healthy, reported, the United State, approved, nine, receiving, the vaccine, New, adenovirus-based, 【제목키워드】 Ad26.COV2.S,